Zhang Yunjing, Wang Ying, Su Xinwan, Wang Ping, Lin Weiqiang
Department of Nephrology, The Fourth Affiliated Hospital, and Institute of Translational Medicine, Zhejiang University School of Medicine, Jinhua, China.
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Oncol. 2021 Oct 14;11:736546. doi: 10.3389/fonc.2021.736546. eCollection 2021.
Liquid biopsy includes non-invasive analysis of circulating tumor-derived substances. It is a novel, innovative cancer screening tool that overcomes the limitations of current invasive tissue examinations in precision oncology. Circular RNA (circRNA) is a recent, novel, and attractive liquid biomarker showing stability, abundance, and high specificity in various diseases, especially in human cancers. This review focused on the emerging potential of human circRNA in body fluids as the liquid biopsy biomarkers for cancers and the methods used to detect the circRNA expression and summarized the construction of circRNA biomarkers in body fluids for treating human cancers and their limitations before they become part of routine clinical medicine. Furthermore, the future opportunities and challenges of translating circRNAs in liquid biopsy into clinical practices were explored.
液体活检包括对循环肿瘤衍生物质的非侵入性分析。它是一种新颖、创新的癌症筛查工具，克服了当前侵入性组织检查在精准肿瘤学方面的局限性。环状RNA（circRNA）是一种最新、新颖且有吸引力的液体生物标志物，在各种疾病，尤其是人类癌症中表现出稳定性、丰度和高特异性。本综述重点关注人circRNA作为癌症液体活检生物标志物在体液中的新兴潜力以及用于检测circRNA表达的方法，并总结了体液中circRNA生物标志物用于治疗人类癌症的构建及其在成为常规临床医学一部分之前的局限性。此外，还探讨了将液体活检中的circRNAs转化为临床实践的未来机遇和挑战。
